Phase Ia/Ib Trial to Evaluate the Tolerability and Safety of IBI101 Monotherapy or in Combination With Sintilimab in Advanced Solid Tumor Patients
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
Price : $35 *
At a glance
- Drugs IBI 101 (Primary) ; Sintilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
- 13 Feb 2019 According to an Innovent Biologics media release, first patient has been dosed. The Investigational New Drug (IND) application of IBI101, indicated for patients with advanced solid tumors, was approved by the U.S. Food & Drug Administration (FDA) on 5 Dec, 2018.
- 24 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 New trial record